Prothena PE Ratio 2011-2022 | PRTA
Current and historical p/e ratio for Prothena (PRTA) from 2011 to 2022. The price to earnings ratio is calculated by taking the latest closing price and dividing it by the most recent earnings per share (EPS) number. The PE ratio is a simple way to assess whether a stock is over or under valued and is the most widely used valuation measure. Prothena PE ratio as of February 03, 2023 is 0.00.
Please refer to the Stock Price Adjustment Guide for more information on our historical prices.
| Prothena PE Ratio Historical Data |
| Date |
Stock Price |
TTM Net EPS |
PE Ratio |
| 2023-02-03 |
57.75 |
|
0.00 |
| 2022-09-30 |
60.63 |
$-3.34 |
0.00 |
| 2022-06-30 |
27.15 |
$-0.24 |
0.00 |
| 2022-03-31 |
36.57 |
$1.22 |
29.98 |
| 2021-12-31 |
49.40 |
$1.09 |
45.32 |
| 2021-09-30 |
71.23 |
$1.03 |
69.16 |
| 2021-06-30 |
51.41 |
$-1.87 |
0.00 |
| 2021-03-31 |
25.12 |
$-3.11 |
0.00 |
| 2020-12-31 |
12.01 |
$-2.79 |
0.00 |
| 2020-09-30 |
9.99 |
$-2.56 |
0.00 |
| 2020-06-30 |
10.46 |
$-2.28 |
0.00 |
| 2020-03-31 |
10.70 |
$-2.02 |
0.00 |
| 2019-12-31 |
15.83 |
$-1.95 |
0.00 |
| 2019-09-30 |
7.84 |
$-1.97 |
0.00 |
| 2019-06-30 |
10.57 |
$-2.10 |
0.00 |
| 2019-03-31 |
12.13 |
$-3.20 |
0.00 |
| 2018-12-31 |
10.30 |
$-3.94 |
0.00 |
| 2018-09-30 |
13.08 |
$-4.62 |
0.00 |
| 2018-06-30 |
14.58 |
$-5.37 |
0.00 |
| 2018-03-31 |
36.71 |
$-4.33 |
0.00 |
| 2017-12-31 |
37.49 |
$-4.06 |
0.00 |
| 2017-09-30 |
64.77 |
$-4.23 |
0.00 |
| 2017-06-30 |
54.12 |
$-4.12 |
0.00 |
| 2017-03-31 |
55.79 |
$-4.84 |
0.00 |
| 2016-12-31 |
49.19 |
$-4.66 |
0.00 |
| 2016-09-30 |
59.97 |
$-4.01 |
0.00 |
| 2016-06-30 |
34.96 |
$-3.48 |
0.00 |
| 2016-03-31 |
41.16 |
$-2.89 |
0.00 |
| 2015-12-31 |
68.11 |
$-2.63 |
0.00 |
| 2015-09-30 |
45.34 |
$-2.35 |
0.00 |
| 2015-06-30 |
52.67 |
$-2.10 |
0.00 |
| 2015-03-31 |
38.14 |
$-1.45 |
0.00 |
| 2014-12-31 |
20.76 |
$-0.12 |
0.00 |
| 2014-09-30 |
22.16 |
$-0.16 |
0.00 |
| 2014-06-30 |
22.55 |
$-0.23 |
0.00 |
| 2014-03-31 |
38.31 |
$-0.93 |
0.00 |
| 2013-12-31 |
26.52 |
$-2.22 |
0.00 |
| 2013-09-30 |
20.23 |
$-2.52 |
0.00 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$2.794B |
$0.201B |
|
Prothena Corp. plc, being a clinical-stage neuroscience company, focused on the development of novel therapeutic therapies for life-threatening diseases. Its wholly owned programs include birtamimab for the potential treatment of AL amyloidosis, PRX004 for the potential treatment of ATTR amyloidosis and a portfolio of programs for the potential treatment of Alzheimer's disease including PRX012 that targets A?.?Prothena is also developing candidates in collaboration with bigwigs like Roche and Bristol-Myers Squibb. These programs include prasinezumab, in collaboration with Roche for the potential treatment of Parkinson's disease and other related synucleinopathies, and programs that target tau, TDP-43 and an undisclosed target in collaboration with Bristol-Myers Squibb for the potential treatment of Alzheimer's disease, amyotrophic lateralsclerosis, etc. It sold PRX004 and the broader ATTR amyloidosis program to Novo Nordisk. It derives revenues from license, development & commercialization agreements.
|
